Affordability

GLP-1 Patient Assistance Programs: A Complete Guide for 2026

7 min read · Published 2026-04-17 · Sources cited to FDA / NIH / clinical trials

Yes, meaningful financial help exists for Ozempic, Wegovy, Mounjaro, and Zepbound in 2026 — but eligibility rules differ sharply by drug, insurance status, and income. Manufacturer savings cards can cut monthly costs to as little as $25 for insured patients, while free-medication programs serve uninsured or low-income patients who meet income thresholds. Knowing exactly which program fits your situation is the fastest path to affordable treatment.

Why Are GLP-1 Medications So Expensive Without Help?

The list price for a monthly supply of GLP-1 receptor agonists used for weight management or type 2 diabetes typically ranges from $900 to $1,400 per month before any discounts or insurance coverage. FDA-approved labeling for both semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) reflects complex biological manufacturing processes that drive high wholesale costs. Many commercial insurance plans still classify weight-loss medications as a non-covered benefit, and Medicare Part D is prohibited by law from covering weight-loss drugs (though diabetes indications may be covered). This creates a significant access gap that manufacturer and nonprofit programs are designed to partially fill.

What Manufacturer Savings Cards Are Available in 2026?

Both Novo Nordisk and Eli Lilly operate direct savings programs for commercially insured patients. These are not available to patients on Medicare, Medicaid, or other federally funded plans.

Medication Indication Program Name Typical Cost Share Annual Cap
Ozempic Type 2 diabetes Novo Nordisk Savings Offer As low as $25/month Check program terms
Wegovy Obesity / weight management Novo Nordisk Savings Offer As low as $0/month (introductory) Check program terms
Mounjaro Type 2 diabetes Lilly Savings Card As low as $25/month Check program terms
Zepbound Obesity / weight management Lilly Savings Card As low as $25/month Check program terms

Important: Savings card terms change frequently. Always verify current amounts directly at novocare.com or lillyanswers.com before enrolling.

What Free Medication Programs Exist for Uninsured or Low-Income Patients?

If you have no insurance or your income falls below a certain threshold, manufacturer Patient Assistance Programs (PAPs) may provide medication at no cost. These programs are separate from savings cards and require a formal application with income documentation.

  • NovoCare Patient Assistance Program (Novo Nordisk): Covers Ozempic and Wegovy for patients who meet income guidelines (generally at or below 400% of the Federal Poverty Level, though thresholds are updated annually). Requires prescriber participation and proof of income.
  • LillyAnswers / Lilly Cares Foundation (Eli Lilly): Covers Mounjaro and Zepbound for qualifying uninsured or underinsured patients. Income limits and residency requirements apply.
  • NeedyMeds.org: A nonprofit database that aggregates PAP applications and eligibility details for both medications. Free to use.
  • RxAssist.org: Another nonprofit directory that helps patients and providers locate and navigate manufacturer PAPs.

Most important takeaway: Manufacturer Patient Assistance Programs — not just savings cards — can provide GLP-1 medications completely free to uninsured or low-income patients who qualify. Most people who could benefit never apply because they don't know these programs exist. Ask your prescriber's office to help you submit the application; many offices have staff dedicated to this process.

How Does the Application Process Work Step by Step?

The timeline below reflects a typical PAP application for either Novo Nordisk or Eli Lilly programs. Individual cases may vary.

Week Step Who Acts
Week 1 Confirm eligibility online or by phone; gather income documents (tax return, pay stubs) Patient
Week 1–2 Prescriber completes clinical section of application and signs Prescriber
Week 2–3 Submit completed application by mail, fax, or online portal Patient or prescriber office
Week 3–5 Manufacturer reviews application; may request additional documents Manufacturer
Week 5–7 Approval notification sent; medication shipped to prescriber's office or pharmacy Manufacturer
Ongoing Re-enrollment required annually; update income documentation Patient + Prescriber

Are There Other Ways to Reduce GLP-1 Costs?

Beyond manufacturer programs, several additional strategies are worth exploring:

  • GoodRx and pharmacy discount cards: Can reduce out-of-pocket cost at retail pharmacies, though savings on GLP-1 medications vary widely and are typically less dramatic than PAP programs.
  • State pharmaceutical assistance programs: Some states offer their own drug assistance for residents who don't qualify for Medicaid. Search your state health department's website.
  • Employer health plan appeals: If your insurer denied coverage, a formal appeal — especially with a letter of medical necessity from your prescriber — can sometimes reverse the decision. The STEP 1 trial (Wilding et al., NEJM 2021) and SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) documenting significant clinical outcomes can support medical necessity arguments.
  • Telehealth platforms: Some telehealth providers offer bundled pricing that includes both prescriber visits and medication at reduced cost, though medication quality and sourcing should be verified carefully.
  • Compounded semaglutide caution: The FDA has warned that compounded versions of semaglutide and tirzepatide may not meet the same safety and efficacy standards as FDA-approved products. Discuss risks with your prescriber before considering compounded alternatives.

Frequently Asked Questions

No. Federal anti-kickback rules prohibit Medicare and Medicaid beneficiaries from using manufacturer copay savings cards. If you have Medicare, ask your prescriber about the Extra Help program (Low Income Subsidy) through Social Security, state pharmaceutical assistance programs, or whether the PAP free-medication route may apply to your situation.
Thresholds vary by program and are updated annually based on Federal Poverty Level guidelines. As a general benchmark, many GLP-1 PAPs have accepted applicants at or below 400% of the FPL, but this is not guaranteed. Check the current year's eligibility criteria directly at novocare.com or lillyanswers.com, or use NeedyMeds.org for up-to-date details.
Most complete applications receive a decision within three to five weeks, though delays occur when documents are missing. Having your prescriber submit the clinical section promptly and submitting income documents at the same time — rather than separately — is the most common way to avoid delays. Some programs offer bridge supplies of medication while the application is processed.
Yes, significantly. Insurance coverage rules treat diabetes and obesity as distinct indications. Ozempic (FDA-approved for type 2 diabetes) and Mounjaro (FDA-approved for type 2 diabetes) are more frequently covered by commercial insurance than Wegovy and Zepbound (approved for chronic weight management). Your prescriber needs to document the specific FDA-approved indication that applies to your case for both insurance and PAP applications.
No. These are separate programs for different eligibility situations. Savings cards are for commercially insured patients; PAPs are for uninsured or underinsured patients with limited income. You apply for whichever matches your current insurance status. If your situation changes — for example, you lose insurance — you can transition from a savings card program to a PAP application.
File a formal insurance appeal with a letter of medical necessity from your prescriber — clinical trial data (such as the STEP 1 and SURMOUNT-1 trials) showing the health impact of GLP-1 therapy can strengthen the argument. Also ask your prescriber whether any alternative FDA-approved medications in the same class are covered under your plan. A patient advocate at NeedyMeds.org or RxAssist.org can also help identify options you may have missed.
Yes, for PAPs. Free medication through manufacturer assistance programs requires annual re-enrollment with updated income documentation. Savings cards for commercially insured patients also typically reset on a calendar-year basis. Set a reminder about 60 days before your enrollment anniversary so there is no gap in your medication supply while paperwork is processed.

Financial assistance for GLP-1 medications is genuinely available in 2026, but the right program depends on your specific insurance status, income, and diagnosis. Your prescriber or their office staff are your best first resource — they deal with these programs regularly and can often accelerate the process. Don't stop or avoid starting treatment because of cost concerns before exploring every option described here.

Sources
  • Novo Nordisk Patient Assistance Program (NovoCare): https://www.novocare.com/
  • Eli Lilly Patient Assistance Program (LillyAnswers): https://www.lillyanswers.com/
  • Ozempic Savings Offer – Novo Nordisk U.S. prescribing information and savings program terms (2024)
  • Wegovy Savings Offer – Novo Nordisk U.S. program terms (2024)
  • Mounjaro Savings Card – Eli Lilly program terms (2024)
  • Zepbound Savings Card – Eli Lilly program terms (2024)
  • FDA-approved labeling: semaglutide injection (Ozempic), semaglutide injection (Wegovy), tirzepatide injection (Mounjaro), tirzepatide injection (Zepbound)
  • NeedyMeds nonprofit drug discount database: https://www.needymeds.org/
  • RxAssist patient assistance program database: https://www.rxassist.org/
  • Wilding JPH et al. (STEP 1 trial). N Engl J Med. 2021;384(11):989-1002.
  • Jastreboff AM et al. (SURMOUNT-1 trial). N Engl J Med. 2022;387(3):205-216.

Keep Reading

Ozempic Nausea: 10 Tips to Feel Better on Injection DayResearch & News · 6 min readTirzepatide Side Effects: What to Expect Week by WeekResearch & News · 7 min read

This site provides general information only and does not constitute medical advice. All content is sourced to FDA labeling, NIH publications, or peer-reviewed clinical trials. Always consult your prescriber before making any medication decision.